<DOC>
	<DOCNO>NCT00708006</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability HGS1029 subject advanced solid tumor determine phase 2 dose .</brief_summary>
	<brief_title>A Study HGS1029 ( AEG40826-2HCl ) Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Confirmed advance solid malignancy Life expectancy least 3 month Age 18 year older Acceptable liver function Acceptable renal function Acceptable hematologic status Received investigational ( yet approve regulatory authority ) agent within 4 week enrollment . Received noninvestigational agent within 3 week enrollment . Progressive CNS involvement include need corticosteroid Pregnant breastfeed woman Active , uncontrolled bacterial , viral , fungal infection within 2 week Cycle 1 Day 1 Known HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>